1. Home
  2. MEI vs LCTX Comparison

MEI vs LCTX Comparison

Compare MEI & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Methode Electronics Inc.

MEI

Methode Electronics Inc.

HOLD

Current Price

$8.50

Market Cap

312.7M

Sector

Technology

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.92

Market Cap

366.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MEI
LCTX
Founded
1946
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
312.7M
366.2M
IPO Year
1994
1996

Fundamental Metrics

Financial Performance
Metric
MEI
LCTX
Price
$8.50
$1.92
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
$11.50
$4.67
AVG Volume (30 Days)
339.5K
1.2M
Earning Date
03-05-2026
01-01-0001
Dividend Yield
2.27%
N/A
EPS Growth
49.14
25.00
EPS
N/A
N/A
Revenue
$908,300,000.00
$9,499,000.00
Revenue This Year
N/A
$6.32
Revenue Next Year
$3.66
$124.49
P/E Ratio
N/A
N/A
Revenue Growth
11.24
6.19
52 Week Low
$5.08
$0.37
52 Week High
$10.97
$2.09

Technical Indicators

Market Signals
Indicator
MEI
LCTX
Relative Strength Index (RSI) 51.32 61.17
Support Level $8.42 $1.55
Resistance Level $8.61 $2.04
Average True Range (ATR) 0.41 0.11
MACD -0.07 0.02
Stochastic Oscillator 22.93 80.82

Price Performance

Historical Comparison
MEI
LCTX

About MEI Methode Electronics Inc.

Methode Electronics Inc supplier of custom-engineered solutions with sales, engineering, and manufacturing locations in North America, Europe, the Middle East, and Asia. It designs, engineers, and produces mechatronic products for Original Equipment Manufacturers (OEMs) utilizing a broad range of technologies for user interface, light-emitting diode (LED) lighting systems, power distribution, and sensor applications. The firm is organized into various business segments: Automotive, Industrial, Interface, and Medical. The Automotive segment, which generates maximum revenue, supplies electronic and electro-mechanical devices and related products to automobiles, including overhead and center consoles, hidden and ergonomic switches, insert molded components, LED-based lighting, and sensors.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: